metricas

Radiología (English Edition)

Suggestions
Radiología (English Edition) Evaluation of the applicability of BI-RADS® MRI for the interpretation of contr...
Journal Information
Vol. 61. Issue 6.
Pages 437-514 (November - December 2019)
Cite
Cite
Share
Download PDF
More article options
Visits
2324
Vol. 61. Issue 6.
Pages 437-514 (November - December 2019)
Original articles

Evaluation of the applicability of BI-RADS® MRI for the interpretation of contrast-enhanced digital mammography

Evaluación de la aplicabilidad del léxico BI-RADS® de la resonancia magnética para la interpretación de la mamografía digital con contraste
Visits
2324
M.M. Travieso-Ajaa, D. Maldonado-Saluzzia, P. Naranjo-Santanaa, C. Fernández-Ruiza, W. Severino-Rondóna, M. Rodríguez Rodrígueza, O.P. Luzardob,c,
Corresponding author
octavio.perez@ulpgc.es

Corresponding author.
a División de diagnóstico de la mama, Departamento de Radiología, Grupo Hospitalario San Roque, Las Palmas de Gran Canaria, Spain
b Instituto de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
c Centro de Investigación Biomédica en Red de Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract
Objective

To determine the usefulness of BI-RADS® MRI for the morphological description and categorization of images obtained with contrast-enhanced digital mammography in comparison with the final diagnosis.

Material and methods

We included patients who had palpable breast lesions, those who needed clarification regarding abnormalities identified with another imaging technique, and those who needed a complementary evaluation of heterogeneously dense breast parenchyma. Three radiologists working independently used a template with the BI-RADS® MRI qualitative descriptors to evaluate the breast lesions studied with contrast-enhanced digital mammography. In a second phase, two other experienced radiologists reached a consensus about discrepant interpretations. Readers also classified each lesion (both benign and malignant lesions) on the BI-RADS® scale (1–5). All the results were compared with the real state of disease (determined by the appropriate gold standard for each type of lesion), and the statistical significance was assessed with the chi-square test.

Results

A total of 218 benign lesions and 426 malignant lesions were included. The interobserver agreement among the three radiologists was high (Fleiss-Cohen kappa = 0.805; 95% CI: 0.728–0.837). Similarly to what has been reported about breast MRI, on contrast-enhanced digital mammography, malignant lesions with mass effect tended to have an irregular shape with spiculated or ill-defined margins and a pattern of intense and heterogeneous enhancement (p < 0.001). Nevertheless, unlike on breast MRI, ring enhancement was not an independent criterion of malignancy on contrast-enhanced digital mammography. For lesions without a mass effect, the only significant descriptor was the intensity of contrast material uptake (p < 0.05). Applying the BI-RADS® MRI material to contrast-enhanced digital mammography images enabled the correct classification of 85% of lesions in the benign categories (BI-RADS 1 and BI-RADS 2 and 3 lesions) and of 93% of the lesions in the malignant categories (BI-RADS 4–5); these values are similar to those reported for breast MRI.

Conclusions

The morphological descriptors used in BI-RADS® MRI can be applied to the morphological analysis of breast lesions studied with contrast-enhanced digital mammography. The partial discrepancies in the interpretation did not influence the final BI-RADS® score, and the score enabled good differentiation between benign and malignant lesions.

Keywords:
Breast cancer
Breast pathology
Contrast-enhanced mammography
Breast magnetic resonance imaging
BI-RADS®
resumen
Objetivo

Se plantea comprobar la utilidad del léxico BI-RADS® de la resonancia magnética de la mama (RMM) para la descripción morfológica y la categorización de las imágenes obtenidas mediante mamografía digital con realce de contraste (CESM) en comparación con el diagnóstico final.

Material y métodos

Se incluyeron pacientes con lesiones de mama palpables o que necesitaban una aclaración de anormalidades previamente identificadas por otra técnica de diagnóstico por imagen, o una evaluación complementaria de parénquima mamario heterogéneamente denso. Tres radiólogos evaluaron de forma independiente las lesiones de mama estudiadas por CESM utilizando una plantilla que contenía los descriptores morfológicos cualitativos del léxico BI-RADS® de la RMM. En una segunda etapa, otros dos radiólogos experimentados proporcionaron una opinión consensuada sobre casos discrepantes. Los lectores también proporcionaron una clasificación en la escala BI-RADS® de 1 a 5 para cada una de las lesiones, tanto benignas como malignas. Todos los resultados se compararon con el estado real de la enfermedad (estándar de referencia apropiado para el tipo de lesión) y la significación estadística fue evaluada mediante la prueba de χ2.

Resultados

El estudio incluyó 218 lesiones benignas y 426 malignas. Hubo un alto acuerdo interobservador entre los tres radiólogos (valor de kappa de Fleiss-Cohen = 0,805; IC al 95% 0,728–0,837). De forma similar a lo que se ha descrito para la RMM, la evaluación de los descriptores morfológicos de las lesiones que dan efecto de masa mostró que las lesiones malignas tienden a presentar una forma irregular, con bordes espiculados o mal definidos y un patrón de realce intenso y heterogéneo (p <  0,001). Sin embargo, a diferencia de la RMM, el patrón de realce en anillo no se puede describir como un criterio independiente de malignidad con esta técnica. Con respecto a las lesiones que no dan efecto de masa, el único descriptor significativo fue la intensidad de la captación del medio de contraste (p < 0,05). La aplicación global del léxico BI-RADS® de la RMM para CESM permitió la clasificación adecuada del 85% de las categorías benignas (BI-RADS 1 y lesiones BI-RADS 2 y 3) y el 93% de las lesiones malignas (BI-RADS 4–5), que son valores similares a los descritos para RMM.

Conclusiones

Los descriptores morfológicos del léxico BI-RADS® de la RMM se pueden aplicar al análisis morfológico de lesiones de mama estudiadas por CESM. Las discrepancias parciales en la interpretación no influyeron en la puntuación final de BI-RADS®, lo que permite una buena diferenciación de las lesiones benignas y malignas.

Palabras clave:
Cáncer de mama
Patología mamaria
Mamografía con contraste
Resonancia magnética de mama
BI-RADS

Article

These are the options to access the full texts of the publication Radiología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
References
[1]
IARC. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and prevalence Worlwide in 2012 2012; Available from: http://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012 (accessed 5 March 2018).
[2]
WHO. WHO position paper on mammography screening 2014:1-84. Disponible en; http://apps.who.int/iris/bitstream/10665/137339/1/9789241507936_eng.pdf?ua=1&ua=1 (acceso 28 de agosto de 2018).
[3]
U.C. Lalji, I.P. Houben, R. Prevos, S. Gommers, M. van Goethem, S. Vanwetswinkel, et al.
Contrast-enhanced spectral mammography in recalls from the Dutch breast cancer screening program: validation of results in a large multireader, multicase study.
Eur Radiol, 26 (2016), pp. 4371-4379
[4]
B.K. Patel, M.B.I. Lobbes, J. Lewin.
Contrast enhanced spectral mammography: a review.
Semin Ultrasound CT MR, 39 (2018), pp. 70-79
[5]
M. Heijblom, J.M. Klaase, F.M. van den Engh, T.G. van Leeuwen, W. Steenbergen, S. Manohar.
Imaging tumor vascularization for detection and diagnosis of breast cancer.
Technol Cancer Res Treat, 10 (2011), pp. 607-623
[6]
C. Dromain, C. Balleyguier, S. Muller, M.C. Mathieu, F. Rochard, P. Opolon, et al.
Evaluation of tumor angiogenesis of breast carcinoma using contrast-enhanced digital mammography.
AJR Am J Roentgenol, 187 (2006), pp. W528-37
[7]
N. Weidner, J.P. Semple, W.R. Welch, J. Folkman.
Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma.
N Engl J Med, 324 (1991), pp. 1-8
[8]
E.M. Fallenberg, C. Dromain, F. Diekmann, F. Engelken, M. Krohn, J.M. Singh, et al.
Contrast-enhanced spectral mammography versus MRI: Initial results in the detection of breast cancer and assessment of tumour size.
Eur Radiol, 24 (2014), pp. 256-264
[9]
C. Dromain, F. Thibault, F. Diekmann, E.M. Fallenberg, R.A. Jong, M. Koomen, et al.
Dual-energy contrast-enhanced digital mammography: initial clinical results of a multireader, multicase study.
Breast Cancer Res, 14 (2012), pp. R94
[10]
M.B. Lobbes, U. Lalji, J. Houwers, E.C. Nijssen, P.J. Nelemans, L. van Roozendaal, et al.
Contrast-enhanced spectral mammography in patients referred from the breast cancer screening programme.
Eur Radiol, 24 (2014), pp. 1668-1676
[11]
M.M. Travieso Aja, M. Rodriguez Rodriguez, S. Alayon Hernandez, V. Vega Benitez, O.P. Luzardo.
Dual-energy contrast-enhanced mammography.
Radiologia, 56 (2014), pp. 390-399
[12]
M.D.M. Travieso-Aja, P. Naranjo-Santana, C. Fernandez-Ruiz, W. Severino-Rondón, D. Maldonado-Saluzzi, M. Rodríguez Rodríguez, et al.
Factors affecting the precision of lesion sizing with contrast-enhanced spectral mammography.
Clin Radiol, 73 (2018), pp. 296-303
[13]
M. Ali-Mucheru, B. Pockaj, B. Patel, V. Pizzitola, N. Wasif, C.C. Stucky, et al.
Contrast-enhanced digital mammography in the surgical management of breast cancer.
Ann Surg Oncol, 23 (2016), pp. 649-655
[14]
M.B. Lobbes, U.C. Lalji, P.J. Nelemans, I. Houben, M.L. Smidt, E. Heuts, et al.
The quality of tumor size assessment by contrast-enhanced spectral mammography and the benefit of additional breast MRI.
J Cancer, 6 (2015), pp. 144-150
[15]
I.P.L. Houben, P. Van de Voorde, C. Jeukens, J.E. Wildberger, L.F. Kooreman, M.L. Smidt, et al.
Contrast-enhanced spectral mammography as work-up tool in patients recalled from breast cancer screening has low risks and might hold clinical benefits.
Eur J Radiol, 94 (2017), pp. 31-37
[16]
B.K. Patel, M.E. Naylor, H.E. Kosiorek, Y.M. Lopez-Alvarez, A.M. Miller, V.J. Pizzitola, et al.
Clinical utility of contrast-enhanced spectral mammography as an adjunct for tomosynthesis-detected architectural distortion.
Clin Imaging, 46 (2017), pp. 44-52
[17]
M. Mori, S. Akashi-Tanaka, S. Suzuki, M.I. Daniels, C. Watanabe, M. Hirose, et al.
Diagnostic accuracy of contrast-enhanced spectral mammography in comparison to conventional full-field digital mammography in a population of women with dense breasts.
Breast Cancer, 24 (2017), pp. 104-110
[18]
V. Richter, V. Hatterman, H. Preibsch, S.D. Bahrs, M. Hahn, K. Nikolaou, et al.
Contrast-enhanced spectral mammography in patients with MRI contraindications.
Acta Radiol, 59 (2018), pp. 798-805
[19]
T.C. Lewis, V.J. Pizzitola, M.E. Giurescu, W.G. Eversman, R. Lorans, K.A. Robinson, et al.
Contrast-enhanced digital mammography: a single-institution experience of the first 208 cases.
Breast J, 23 (2017), pp. 67-76
[20]
A.S. Tagliafico, B. Bignotti, F. Rossi, A. Signori, M.P. Sormani, F. Valdora, et al.
Diagnostic performance of contrast-enhanced spectral mammography: systematic review and meta-analysis.
[21]
E.S. Burnside, E.A. Sickles, L.W. Bassett, D.L. Rubin, C.H. Lee, D.M. Ikeda, et al.
The ACR BI-RADS experience: learning from history.
J Am Coll Radiol, 6 (2009), pp. 851-860
[22]
F. Thibault, C. Balleyguier, A. Tardivon, C. Dromain.
Contrast enhanced spectral mammography: better than MRI?.
Eur J Radiol, 81 (2012), pp. S162-S164
[23]
R.M. Kamal, M.H. Helal, S.M. Mansour, M.A. Haggag, O.M. Nada, I.G. Farahat, et al.
Can we apply the MRI BI-RADS lexicon morphology descriptors on contrast-enhanced spectral mammography?.
Br J Radiol, 89 (2016),
[24]
R.M. Kamal, M.H. Helal, R. Wessam, S.M. Mansour, I. Godda, N. Alieldin.
Contrast-enhanced spectral mammography: impact of the qualitative morphology descriptors on the diagnosis of breast lesions.
Eur J Radiol, 84 (2015), pp. 1049-1055
[25]
S. Badr, N. Laurent, C. Regis, L. Boulanger, S. Lemaille, E. Poncelet.
Dual-energy contrast-enhanced digital mammography in routine clinical practice in 2013.
Diagn Interv Imaging, (2014), pp. 245-258
[26]
N.A. Obuchowski.
Receiver operating characteristic curves and their use in radiology.
Radiology, 229 (2003), pp. 3-8
[27]
M. Wallis, C. Borrelli, S. Cohen, et al.
Clinical guidance for breast cancer screening assessment.
(2016),
[28]
J.L. Fleiss.
Measuring nominal scale agreement among many raters.
Psychol Bull, 76 (1971), pp. 378-384
[29]
A. Alikhassi, H. Esmaili Gourabi, M. Baikpour.
Comparison of inter- and intra-observer variability of breast density assessments using the fourth and fifth editions of Breast Imaging Reporting and Data System.
Eur J Radiol Open, 5 (2018), pp. 67-72
[30]
M.D. Travieso Aja, G. Santana Lopez, M. Rodriguez Rodriguez, O.P. Luzardo.
Is contrast-enhanced spectral mammography (CESM) helpful in differentiating diabetic mastopathy from breast carcinoma?.
J Med Imaging Radiat Oncol, 60 (2016), pp. 639-641
[31]
L. Liberman, G. Mason, E.A. Morris, D.D. Dershaw.
Does size matter? Positive predictive value of MRI-detected breast lesions as a function of lesion size.
AJR Am J Roentgenol, 186 (2006), pp. 426-430
[32]
C.J. D’Orsi, E.A. Sickles, E.B. Mendelson, E.A. Morris.
ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System.
American College of Radiology, (2013),
[33]
Q. Wang, K. Li, L. Wang, J. Zhang, Z. Zhou, Y. Feng.
Preclinical study of diagnostic performances of contrast-enhanced spectral mammography versus MRI for breast diseases in China.
Springerplus, 5 (2016), pp. 763
[34]
M.D. Travieso Aja, P. Munoz, M. Rodriguez Rodriguez, V. Vega Benitez, O.P. Luzardo.
A case of a concurrent and co-located invasive carcinoma and a fibroadenoma to illustrate the potential of dual-energy, contrast-enhanced digital mammography on the diagnosis of complex breast lesions.
Iran J Radiol, 13 (2016),
[35]
F. Sardanelli, E.M. Fallenberg, P. Clauser, R.M. Trimboli, J. Camps-Herrero, T.H. Helbich, et al.
Mammography: an update of the EUSOBI recommendations on information for women.
Insights Imaging, 8 (2017), pp. 11-18
[36]
E.M. Fallenberg, F.F. Schmitzberger, H. Amer, et al.
Contrast-enhanced spectral mammography vs. mammography and MRI – clinical performance in a multi-reader evaluation.
Eur Radiol, 27 (2017), pp. 2752-2764
[37]
T. Knogler, P. Homolka, M. Hoernig, R. Leithner, G. Langs, M. Waitzbauer, et al.
Application of BI-RADS Descriptors in Contrast-Enhanced Dual-Energy Mammography: Comparison with MRI.
Breast Care (Basel), 12 (2017), pp. 212-216
[38]
K. Pinker-Domenig, W. Bogner, S. Gruber, H. Bickel, S. Duffy, M. Schernthaner, et al.
High resolution MRI of the breast at 3 T: which BI-RADS® descriptors are most strongly associated with the diagnosis of breast cancer?.
Eur Radiol, 22 (2012), pp. 322-330
[39]
G. Agrawal, M.Y. Su, O. Nalcioglu, S.A. Feig, J.H. Chen.
Significance of Breast Lesion Descriptors in the ACR BI-RADS MRI Lexicon.
Cancer, 115 (2009), pp. 1363-1380
[40]
W. Fujiwara, T. Yamada, Y. Kanemaki, S. Okamoto, Y. Kojima, K. Tsugawa, et al.
Grading system to categorize breast MRI in BI-RADS 5th edition: a multivariate study of breast mass descriptors in terms of probability of malignancy.
AJR Am J Roentgenol, 210 (2018), pp. W118-W127
[41]
T. Asada, T. Yamada, Y. Kanemaki, K. Fujiwara, S. Okamoto, Y. Nakajima.
Grading system to categorize breast MRI using BI-RADS 5th edition: a statistical study of non-mass enhancement descriptors in terms of probability of malignancy.
Jpn J Radiol, 36 (2018), pp. 200-208
[42]
B. Bennani-Baiti, P.A. Baltzer.
MR imaging for diagnosis of malignancy in mammographic microcalcifications: a systematic review and meta-analysis.
Radiology, 283 (2017), pp. 692-701
asdasdasd
Article options
Tools